Akèy › Maladi Crohn › New York › New York City
Etid klinik pou Maladi Crohn nan New York City, NY
35 etid pou Maladi Crohn ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Ap rekriteFaz 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Ap rekriteFaz 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Ap rekriteFaz 3
- NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
- Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
- New York Gastroenterology Associates ( Site 5013), New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ap rekriteFaz 4
- New York Gastroenterology Associates, New York
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Ap rekriteFaz 2
- Northwell Health-Lenox Hill Hospital /ID# 265527, New York
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- New York Gastroenterology Associates, New York
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2/3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Weill Cornell Medical College, New York
- Lenox Hill Hospital, New York
- ak 1 plis
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Ap rekriteFaz 3
- New York Gastroenterology Associates, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- Manhattan Clinical Research, LLC-Site Number: 8400069, New York
- NYU Langone Health-Site Number: 8400091, New York
- Columbia University Medical Center-Site Number: 8400138, New York
- ak 2 plis
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- NYU Langone Health-Site Number: 8400091, New York
- Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
- New York Gastroenterology Associates-Site Number: 8400009, New York
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai /ID# 254880, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Ap rekriteFaz 4
- NYU Langone Health, New York
Standardized Microbiota Transplant Therapy in Crohn's Disease
Ap rekriteFaz 2
- NYU Langone Health, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- New York Gastroenterology Associates, New York
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Ap rekriteFaz 3
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Ap rekriteFaz 3
- Weill Cornell Medicine, New York
Behavioral Therapy for Crohn's Disease
Ap rekrite
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Ap rekrite
- NYU Langone Health, New York
- Cornell University, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Ap rekriteEtid obsèvasyon
- New York University, New York
Low Dose IL-2 for the Treatment of Crohn's Disease
Ap rekriteFaz 1/2
- Mount Sinai, New York
Autologous Stem Cell Transplant for Crohn's Disease
Ap rekriteFaz 2
- Icahn School of Medicine at Mount Sinai, New York
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai /ID# 262216, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ap rekriteFaz 3
- New York Presbyterian Hospital, New York
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Ap rekriteFaz 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Ap rekriteFaz 3
- Columbia University Medical Center, New York-Presbyterian Hospital, New York
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Ap rekriteFaz 4
- Columbia University Medical Center, New York
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
Ap rekrite
- Weill Cornell Medical College, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Ap rekriteFaz 2
- Mirador Therapeutics Selected Site, New York
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Icahn School of Medicine at Mount Sinai, New York
Treatment of Moderate to Severe Refractory Crohn's Disease
Ap rekriteFaz 1/2
- Mount Sinai Health Systems, New York
Helmsley 3.0: Abbreviated MRE
Ap rekriteEtid obsèvasyon
- NYU Langone, New York
Etid Maladi Crohn nan lòt vil
- Boston, MA19 etid
- Miami, FL19 etid
- Cleveland, OH19 etid
- St. Louis, MO19 etid
- Tyler, TX17 etid
- Houston, TX17 etid
- Orlando, FL17 etid
- Atlanta, GA17 etid
- San Antonio, TX15 etid
- San Diego, CA15 etid
- Los Angeles, CA15 etid
- Colorado Springs, CO13 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.